Additional stimulation of sgc on top of standard treatment with arb`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to arb treatment alone

HIGHLIGHTS

• who: Alter et_al BMC Pharmacology and collaborators from the Germany Institute for Nutritional Science, University of Potsdam, Germany. , Bayer HealthCare AG, Cardiovascular Research, Wuppertal, Germany. , Institute of Pharmacy, Martin-Luther-University of Halle, Germany. Published: , August , have published the paper: Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone, in the Journal: (JOURNAL)
• what: Riociguat significantly reduced urinary albumin excretion in diabetic eNOS knock out mice that were refractory to treatment with ARB's alone . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.